IMSR Seminar Series: Mechanism and novel therapies to treat NASH driven HCC

Professor Mark Febbraio, Senior Principal Research Fellow of the NHMRC, and the Head of the Cellular and Molecular Metabolism Laboratory within the Drug Discovery Programme at Monash Institute of Pharmaceutical Sciences, Monash University Australia will give a talk on 'Mechanism and novel therapies to treat NASH driven HCC.'

Professor Febbraio is also the CSO of N-Gene Research Laboratories Inc., a USA based Biotechnology Company and the Founder and CSO of the recently incorporated company Kinomedica. His research is focussed on understanding cellular and molecular mechanisms associated with exercise, obesity, type 2 diabetes and cancer and his aim is to develop novel drugs to treat lifestyle related diseases.

He has authored over 250 peer reviewed papers in leading journals and has over 30,000 career citations. He has won prizes at international, national and institutional levels including the A K McIntyre Prize for significant contributions to Australian Physiological Science (1999), the Colin I Johnson Lectureship by the High Blood Pressure Research Council of Australia (2006) the ESA/ADS Joint Plenary Lecture (2009), the Sandford Skinner Oration from the University of Melbourne (2011), Eureka Scientific Prize Finalist (2013) and the Kellion Award for the Australian Diabetes Society (2017).

Registration isn't required for this event.